论文部分内容阅读
CA-50是一种新的肿瘤相关抗原,为了估价CA-50诊断胃肠癌的实用价值,作者检测244例各种胃肠癌患者和190例各种良性胃肠疾病患者血清 CA-50的含量(诊断临界值为17U/ml),同时检测这些患者的癌胚抗原(CEA,诊断临界值为2.5ng/ml)和甲(?)蛋白(AFP,诊断临界值25ng/ml),并进行了比较,结果如下。结直肠疾患原发性结直肠癌 CA-50升高者占37%(21/51),最高达16000U/ml,复发性癌症升高的患者占49%(17/35),良性结直肠疾患则仅有6%的患者轻度升高,其含量为42U/ml。结直肠癌患者和良性病患者分别有67%与21%CEA 升高,而
CA-50 is a novel tumor-associated antigen. In order to evaluate the practical value of CA-50 in the diagnosis of gastrointestinal cancer, the authors detected serum CA-50 in 244 patients with various gastrointestinal cancers and 190 patients with various benign gastrointestinal diseases. Content (diagnostic cut-off value is 17 U/ml), simultaneous detection of carcinoembryonic antigen (CEA, diagnostic threshold 2.5 ng/ml) and alpha (AFP), diagnostic threshold 25 ng/ml for these patients, and For comparison, the result is as follows. Patients with colorectal cancer with elevated colorectal cancer (CA-50) accounted for 37% (21/51) of the colorectal cancer, up to 16,000 U/ml, 49% (17/35) with recurrent cancer, and benign colorectal disease. Only 6% of patients had a slight increase and their content was 42 U/ml. In patients with colorectal cancer and benign disease, there was a 67% and 21% increase in CEA, respectively.